Clinical trials: Dementia Mild
Cognitive Impairment, Alzheimer Disease
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
The clinical evaluation of a patient with a cognitive complaint requires neuropsychological tests, evaluating the integrity of memory and other cognitive functions.
- Trial name
- MemScreen (NCT03811184)
- Testing
- MemScreen
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MemScreen
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
This study will investigate the performance of physician readers trained to read florbetapir-PET scans using electronic media training.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01550549
- Testing
- florbetapir F 18
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01343966
- Testing
- MABT5102A
- Where
- 92 sites in United States, Canada and 4 more
- Volunteers
- 448 people
- Sponsor
- Genentech, Inc.
Alzheimer's Disease
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARBEAM (NCT02006641)
- Testing
- Idalopirdine
- Where
- 162 sites in United States, Argentina and 17 more
- Volunteers
- 858 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT01549834
- Testing
- ABT-126
- Where
- 43 sites in United States, Canada and 5 more
- Volunteers
- 434 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Healthy Aging, Alzheimer's Disease
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
This single-session, within-subject, sham-controlled early feasibility study evaluated the safety, tolerability, and feasibility of delivering 40 Hz audiovisual (gamma sensory) stimulation through a virtual reality (VR) headset…
- Conditions
- Healthy Aging, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- CFS (NCT06234930)
- Testing
- Audiovisual stimulation VR system
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Clarity Health Technologies, Inc
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's and Blood Glucose Levels
The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of early detection of Alzheimer's…
- Trial name
- NCT04614376
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bio Conscious Technologies Inc.
Alzheimer's Disease
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
This study will evaluate safety and efficacy of PF-05212377 in subjects with mild-to-moderate Alzheimer's Disease with existing neuropsychiatric symptoms on a stable dose of Donepezil.
- Trial name
- NCT01712074
- Testing
- PF-05212377 (SAM-760)
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 186 people
- Sponsor
- Pfizer
Alzheimer Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease.
- Trial name
- NCT05466422
- Testing
- MK-2214
- Where
- 12 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Alzheimer's Disease
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).
- Trial name
- STARBRIGHT (NCT02006654)
- Testing
- Idalopirdine
- Where
- 107 sites in United States, Australia and 13 more
- Volunteers
- 734 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
- Trial name
- NCT01548430
- Testing
- TTP4000
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- vTv Therapeutics
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour.
- Trial name
- PRImus-AD (NCT06182085)
- Testing
- PRI-002
- Where
- 38 sites in Czechia, Germany and 4 more
- Volunteers
- 304 people
- Sponsor
- PRInnovation GmbH
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission…
- Trial name
- SUMMIT AD (NCT01254773)
- Testing
- Experimental Bapineuzumab
- Where
- 28 sites in United States
- Volunteers
- 146 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo…
- Trial name
- NCT00930059
- Testing
- PF-04447943
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when…
- Trial name
- INTERCEPT-AD (NCT04931459)
- Testing
- ACU193
- Where
- 17 sites in United States
- Volunteers
- 65 people
- Sponsor
- Acumen Pharmaceuticals
Dementia Alzheimers
Feasibility Study of Game Technology in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
This study will test G:DATA, a simple computer game designed to diagnose Alzheimer's Disease, in three different groups of people, some of whom have Alzheimer's Disease.
- Trial name
- G:DATA (NCT06047340)
- Testing
- G:DATA, dementia screen videogame
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ascentys Ltd
MCI, Mild Cognitive Impairment
The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI)
The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for…
- Conditions
- MCI, Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- iPACES (NCT05009524)
- Testing
- iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- iPACES LLC